CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
TRS01 eye drops +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04222712
NCT04222712Phase 2Completed

A Randomized, Double-Masked, Dose-Ranging Study to Evaluate the Safety and Tolerability of TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis.

Tarsier Pharma·interventional·Posted Jan 10, 2020·Updated Oct 5, 2023

In Brief

A Phase 2 clinical trial evaluating TRS01 eye drops for Non-infectious Anterior Uveitis. Completed, enrolled 16 participants across 2 sites.

Detailed Summary

The objective of this study is to evaluate the safety of TRS01 eye drops in participants with active non-infectious anterior uveitis .

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedJan 10, 2020
Enrollment StartFeb 1, 2020
Primary CompletionAug 24, 2020
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 6.5 years ago

Interventions

TRS01 eye dropsdrug

Dosed four times a day (QID)

TRS01 eye dropsdrug

Dosed four times a day (QID)